1-哌嗪羧酸甲酯盐酸盐置于potassium Hydroxide体系中,用 二氯甲烷 作为反应溶剂,化学反应 1.0H,以14.5 G的收率获得产物哌嗪-1-羧酸甲酯 参考文献: Alternate Processes For The Preparation Of Omecamtiv Mecarbil[fr] Nouveaux Procédés Destinés à La Préparation De L'Omécamtiv Mécarbil 标题: Alternate Processes For The Preparation Of Omecamtiv Mecarbil[fr] Nouveaux Procédés Destinés à La Préparation De L'Omécamtiv Mécarbil 摘要:本申请的方面涉及制备omecamtiv Mecarbil及其盐的过程.具体方面涉及新型尿素中间体,其制备过程及其在制备omecamtiv Mecarbil及其盐中的应用.改进的omecamtiv Mecarbil制备过程具有工业可行性.
专利号:US-11702380-B2 优先权日:2021-03-10 标 题:Synthesis of omecamtiv mecarbil 发明人:CAILLE SEBASTIEN; MURRAY JAMES; QUASDORF KYLE; NGUYEN HANNAH; SILVA ELIPE MARIA VICTORIA; ERICSON ARI ELIZABETH 权利人:AMGEN INC 摘要:Provided herein are synthetic methods for the preparation of intermediates that are utilized in the synthesis of omecamtiv mecarbil dihydrochloride.
专利号:US-12269811-B2 优先权日:2017-06-30 标 题:Synthesis of omecamtiv mecarbil 发明人:CAILLE SEBASTIEN; QUASDORF KYLE; ROOSEN PHILIPP C; SHI XIANQING; COSBIE ANDREW; WANG FANG; WU ZUFAN; NEERGUNDA ARCHANA; QUAN BIN PETER; GUAN LIANXIU 权利人:AMGEN INC 摘要:Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (1)
专利号:US-10995078-B2 优先权日:2013-03-13 标 题:Compounds and compositions for inhibition of FASN 发明人:BAIR KENNETH W; LANCIA JR DAVID R; LI HONGBIN; LOCH JAMES; LU WEI; MARTIN MATTHEW W; MILLAN DAVID S; SCHILLER SHAWN E R; TEBBE MARK J 权利人:FORMA THERAPEUTICS INC 摘要:The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:
专利号:US-2023373955-A1 优先权日:2017-06-30 标 题:Synthesis of omecamtiv mecarbil
专利号:US-2022298099-A1 优先权日:2021-03-10 标题:Synthesis of omecamtiv mecarbil
专利号:TW-202300479-A 优先权日:2021-03-10 标 题:Synthesis of omecamtiv mecarbil
摘要:Xing, Y.-K.; Fang, P.; Wang, Z.-H.; Mei, T.-S., Science of Synthesis: Special Topics, (2021) 1, 138. 参考文献:10.1038/ncomms14193|10.1038/ncomms15273 摘要:Pegoraro S, Duffey M, Otto TD, Wang Y, Rösemann R, Baumgartner R, Fehler SK, Lucantoni L, Avery VM, Moreno-Sabater A, Mazier D, Vial HJ, Strobl S, Sanchez CP, Lanzer M. Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria. Nature Communications. 2017 Apr 06;8(1):15273. doi: 10.1038/ncomms15273.